Sirnaomics Ltd. (stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with strong presence in both China and the U.S., and the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) on December 30, 2021.

For the IPO, Commerce & Finance and Clifford Chance advised the issuer; Jingtian & Gongcheng and Wilson Sonsini Goodrich & Rosati advised the joint sponsors.